Mayo Clinic researchers have validated a blood test's high precision for diagnosing patients with cognitive impairment.This non-invasive, cost-effective breakthrough, detailed in Alzheimer's & Dementia, offers much-needed hope for earlier intervention and better management.
Alzheimer's disease, a devastating neurological condition characterised by progressive memory loss and cognitive decline, affects millions worldwide. The profound impact extends beyond patients to their families and caregivers. While new treatments are emerging for individuals in the early stages of the disease, a critical challenge remains: the need for accessible, cost-effective, and accurate diagnostic tools to identify Alzheimer's sooner.
In a significant stride forward, Mayo Clinic researchers have validated the accuracy of an FDA-approved blood test that promises to revolutionise Alzheimer's diagnosis. This accessible test, suitable for use in outpatient memory clinics, demonstrated high accuracy in diagnosing the disease across a spectrum of cognitive impairments. The groundbreaking findings are published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Traditionally, diagnosing Alzheimer's disease has relied on methods such as positron emission tomography (PET) scans and spinal taps, which measure the buildup of toxic proteins in the brain. However, these procedures are often expensive and invasive, limiting their widespread applicability. The urgent need for more accessible, non-invasive, and cost-effective biomarkers – measurable indicators of a disease – has been a driving force in Alzheimer's research. This new blood test addresses that critical need, paving the way for improved diagnoses in diverse clinical settings.
The research team highlights the immense potential of their findings, stating that this blood test can significantly contribute to better identifying research participants with Alzheimer's disease brain changes, efficiently screening and selecting patients with Alzheimer's disease for clinical trials, and more effectively assessing patient response to therapy in clinical trials.
The study involved over 500 patients receiving treatment for various memory issues at the outpatient Memory Disorder Clinic at the Mayo Clinic in Florida. The diverse patient cohort included individuals with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia, and vascular cognitive impairment. Patients ranged in age from 32 to 89, with the average age of symptom onset at 66. Alzheimer's disease was determined to be the underlying cause of symptoms in 56% of the participants. The research team also conducted serum tests to measure kidney disease, a factor that can influence plasma biomarker concentrations.
Mayo Clinic Laboratories conducted tests for two key proteins in blood plasma associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: Aβ42/40 and p-tau217. The results revealed significantly higher levels of p-tau217 in patients diagnosed with Alzheimer's disease compared to those without the condition. Importantly, the researchers also observed that higher plasma p-tau217 concentrations were associated with impaired kidney function, underscoring the importance of considering this factor when interpreting blood test results.
Out of 509 patients, plasma p-tau217 concentrations were positive in 267 individuals. Notably, this included 233 out of 246 patients (95%) whose cognitive impairment was attributed to Alzheimer's disease, demonstrating the test's remarkable accuracy.
The study's compelling findings were prominently featured at the American Academy of Neurology Annual Meeting in April, generating significant interest within the medical community. This research builds upon a previous study by the Mayo Clinic Laboratories team, which demonstrated the utility of these blood tests in comparison to amyloid PET scans in research participants.
Looking ahead, Dr. Day, a lead researcher on the study, emphasised the next crucial steps. The team plans to evaluate blood-based testing in more diverse patient populations and in individuals with early Alzheimer's disease who may not yet exhibit cognitive symptoms. Furthermore, they aim to investigate disease-specific factors that could potentially alter biomarker accuracy in clinical trials.
This breakthrough in blood testing offers a promising future for Alzheimer's diagnosis, enabling earlier intervention, facilitating more effective clinical trials, and ultimately providing new hope for patients and their families.
China has achieved a significant medical milestone, with its drug regulator announcing the approval of the country's first domestically developed 9-valent human papillomavirus (HPV) vaccine.
The UK has officially banned the sale of disposable vapes as of Sunday, aiming to curb youth usage, reduce environmental waste, and stop the spread of harmful chemicals.
The U.S. FDA has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for adults aged 65 and older and those aged 12–64 with risk factors, marking a major step under tighter regulations.
Researchers have developed a new testing method that could diagnose brain tumors within hours, potentially allowing treatment to begin during surgery.
World leaders pledged over $170 million to WHO at the 2025 World Health Assembly in Geneva, reinforcing global support for multilateral health efforts.
Thailand has closed two tourist border crossings with Cambodia following a military skirmish that raised tensions between the two neighbors.
A man drove a car into a group of people in the southern German city of Passau on Saturday. Police say the motive may be personal and have not ruled out that the act was deliberate.
Russia carried out a large-scale air attack on the eastern Ukrainian city of Kharkiv overnight and into Saturday evening, killing at least four people and injuring more than 60 others, including a baby, according to local officials.
Chinese Vice Premier He Lifeng will visit the UK from June 8–13 for the first round of China-U.S. economic and trade consultations. Talks will include U.S. Treasury and Commerce Secretaries and Trade Representative Jamieson Greer.
U.S. President Donald Trump has warned that there could be “serious consequences” if Elon Musk provides financial support to Democratic candidates challenging Republicans who back Trump’s tax-cut bill, signalling a sharp turn in their previously cordial relationship.
A bridge collapse in the Vygonichsky district of Russia’s Bryansk region, near the Ukrainian border, caused a train derailment and a traffic accident early Sunday, killing at least seven people and leaving 30 injured, according to emergency services.
Ukraine’s Security Service (SBU) has confirmed it carried out a third targeted attack against the Crimean Bridge, also known as the Kerch Bridge, early Tuesday morning, marking a new escalation in the ongoing conflict with Russia.
A strong 6.3 magnitude earthquake shook Japan’s Hokkaido prefecture early Monday, causing no reported injuries or damage, and no tsunami warning was issued, officials confirmed.
U.S. President Donald Trump and Chinese President Xi Jinping are expected to speak this week to discuss recent trade tensions, White House press secretary Karoline Leavitt said.
Peace talks between Russia and Ukraine ended abruptly in Istanbul on Monday, lasting just over an hour amid mounting tensions following a major Ukrainian drone strike on Russian strategic bombers and renewed pressure from the U.S. for a breakthrough.
US President Donald Trump signed an executive order Friday to ease restrictions on American drones and help the industry compete with China.
Vietnam has officially abolished its long-standing two-child policy in a bid to counter declining birth rates and a shrinking workforce.
China has achieved a significant medical milestone, with its drug regulator announcing the approval of the country's first domestically developed 9-valent human papillomavirus (HPV) vaccine.
Radionuclide therapy using the radioactive element terbium shows promising potential in treating lymphoma, according to recent experimental results from the Paul Scherrer Institute (PSI) in collaboration with Inselspital – Bern University Hospital.
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
Thailand has closed two tourist border crossings with Cambodia following a military skirmish that raised tensions between the two neighbors.
A man drove a car into a group of people in the southern German city of Passau on Saturday. Police say the motive may be personal and have not ruled out that the act was deliberate.
Russia carried out a large-scale air attack on the eastern Ukrainian city of Kharkiv overnight and into Saturday evening, killing at least four people and injuring more than 60 others, including a baby, according to local officials.
Chinese Vice Premier He Lifeng will visit the UK from June 8–13 for the first round of China-U.S. economic and trade consultations. Talks will include U.S. Treasury and Commerce Secretaries and Trade Representative Jamieson Greer.
U.S. President Donald Trump has warned that there could be “serious consequences” if Elon Musk provides financial support to Democratic candidates challenging Republicans who back Trump’s tax-cut bill, signalling a sharp turn in their previously cordial relationship.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment